COVID-19 is robust in both those who are only mildly ill and those who are critically ill.Researchers are hoping to learn more about exactly how the antibodies work with a goal of improving patient outcomes by helping to pinpoint who would require certain treatments.
Coronavirus — meet the Ontario researchers responsible for 3 world-firsts The small study involved 56 people in four groups of 14: critically ill patients at London Health Sciences Centre (LHSC) with COVID-19, critically ill patients who tested negative for COVID-19, people who were mildly ill with COVID-19 and did not require hospitalization, and healthy controls.